SCHEMBL9911836

SCHEMBL9911836

CC(C)N(C)c1ccccc1CN1CCC(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CCR5 P51681 1/20 0.52
▸ KCNA3 P22001 1/20 0.51
▸ DRD2 P14416 4/20 0.47
▸ KMT2A Q03164 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CKS1B P61024 1/20 0.43
▸ SKP1 P63208 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ USP14 P54578 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ SIGMAR1 Q99720 3/20 0.42
▸ NAMPT P43490 1/20 0.42
▸ KDM1A O60341 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ AKT1 P31749 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9911767 0.90 KCNA3 (0.53) CCR5KCNA3DRD2KMT2AL3MBTL1
SCHEMBL4208497 0.86 POLB (0.49) L3MBTL1POLBSIGMAR1
SCHEMBL12533621 0.81 SIGMAR1 (0.63) KCNA3DRD2KMT2AL3MBTL1POLB
SCHEMBL915402 0.79 KMT2A (0.65) KCNA3DRD2KMT2AL3MBTL1POLB
SCHEMBL9911771 0.78 SIGMAR1 (0.60) KCNA3DRD2KMT2AL3MBTL1SIGMAR1
SCHEMBL9911792 0.77 KCNA3 (0.45) CCR5KCNA3DRD2KMT2AL3MBTL1
SCHEMBL9911769 0.76 KCNA3 (0.47) CCR5KCNA3DRD2KMT2AL3MBTL1
SCHEMBL31653647 0.75 KCNA3 (0.48) CCR5KCNA3DRD2KMT2AL3MBTL1
SCHEMBL11969521 0.75 KCNA3 (0.58) CCR5KCNA3DRD2KMT2AL3MBTL1
SCHEMBL555464 0.75 KMT2A (0.64) KCNA3DRD2KMT2AL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193203-B2 Bicyclic compounds having activity at the CXCR4 receptor ALLERGAN, INC. (US) 2012-06-05 — — US disclosed
US-8193203-B2 Bicyclic compounds having activity at the CXCR4 receptor ALLERGAN, INC. (US) 2012-06-05 — — US disclosed
CN-102105463-A Bicyclic compounds active on the CXCR4 receptor ALLERGAN INC 2011-06-22 — — CN disclosed
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-12-17 — — US disclosed
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-12-17 — — US disclosed
WO-2009143058-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR CXCR4, CXCR2, CXCL12 CCR5 5/4885KCNA3 3430/4885DRD2 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback